Dengue-positive serum samples that had been previously analyzed and serotyped in our laboratory were used as positive controls. Samples that were collected after 6 or more days of onset of symptoms were analyzed by using either the dengue IgM capture 
| INTRODUCTION
Dengue virus (DENV) has been circulating in Brazil since the 1980s, with the first outbreaks occurring mainly in the southeast and northern regions. 1 By the 1990s, most Brazilian states were reporting DENV infection, including autochthonous cases; however, in Rio Grande do Sul (RS), the southernmost Brazilian state, the first autochthonous case was reported only in 2007, more than 40 years after the introduction of DENV into the country. The main symptoms of dengue fever are headache, sudden onset of fever, retro-orbital pain, body aches, nausea and vomiting, joint pains, weakness, and rash. With the recent introduction of Chikungunya virus (CHIKV) and Zika virus (ZIKV) in Brazil in 2014, which infect humans causing symptoms similar to dengue fever, the correct diagnosis of these infections became challenging. Even though laboratory tests have been developed to discriminate among DENV, CHIKV, and ZIKV, these assays might yield confounding results mainly due to cross-reacting antibodies presented by people who had been previously infected or vaccinated against a flavivirus (such as yellow fever). 3 Therefore, diagnosis of these arboviral diseases relies not only 2 | MATERIAL AND METHODS
| Patients and samples
This study includes analyses of human blood samples sent to the Dengue virus 1 was the most prevalent serotype circulating in RS during this period (97.5% of the cases). Although DENV-2, DENV-3, and DENV-4 were also identified, they referred to imported cases, except for 1 autochthonous case of DENV-4 that was confirmed in 2014.
Dengue fever occurred mainly in adults, with similar distribution among age groups. Nevertheless, some age groups showed frequencies higher than the statistically expected: in 2014, prevalence was high in the age group 21 to 30 years old, in 2015 in adults older than 41 years old, and in 2016 in the age group 11 to 20 years old (Table 1) .
There was no difference in prevalence of DENV infection between men and women in the period analyzed (P = .4) ( Table 1) . Of note, of all patients investigated, 87 were pregnant women and, of these, 19 were positive for DENV ( Table 1) .
The symptoms most reported by infected patients were fever, myalgia, and headache, followed by retro-orbital pain, nausea, exanthema, and arthralgia; vomiting, leucopenia, and petechia, though less common symptoms, were also reported ( Figure 1A 
| DISCUSSION
Dengue virus was introduced into Brazil more than 30 years ago, causing outbreaks in most states. In RS, however, the first notification The results presented herein reinforce that a significant and constant increase in the number of DENV cases is occurring in RS.
The recent introduction of CHIKV and ZIKV in the state 15 has posed a concern to the population and health authorities, and this might have Aedes has increased in the last years. 18 Even though Aedes aegypti is the predominant DENV vector in RS, the climate in the region also favors the spread of Aedes albopictus, 19 which can survive in a variety of larval habitats and resist lower temperatures than Ae. aegypti.
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In our study, the number of dengue cases in RS increased after periods of high precipitation and, mainly, high temperatures. A recent study conducted in Porto Alegre, the capital of RS, found that minimum temperatures above 18°C were strongly associated with increased Aedes mosquito abundance, whereas humidity above 75%
had a negative effect on it; also, dengue cases occurred when the number of adult mosquitoes was high. 21 Another study suggests that low temperatures in RS as compared with other Brazilian states might be associated with a decrease in the mosquito vector population and, consequently, a reduction in DENV infection between July and November. 22 Accordingly, in our study, these were the months with the lowest number of DENV cases in all years analyzed (2014-2016), and average minimum temperatures from July to November were below 16.7°C. In addition, we also found a small number of cases in the northeastern region of RS, where temperatures are low even in the summer, and in the southern region, where precipitation is low; such conditions are not favorable for the development of eggs of Aedes mosquitoes. 22 It is important to take into account that the municipalities that have previous reports of DENV circulation and of
Aedes infestation are usually more alert in controlling the disease and in fact become endemic areas; thus, a more constant surveillance and notification in these places tends to pose a reporting bias by region.
While meteorological conditions may favor the vector, other factors also have an impact on the spread of the virus, such as transportation, tourism, sanitary conditions, and even host immunity.
For example, while previous infection can worsen the symptoms, vaccination against other flavivirus such as yellow fever might provide some cross protection against DENV. 23 Considering that great part of RS is within the area of recommendation for yellow fever vaccination, 24 this is a factor that should be taken into account when investigating a patient with symptoms of arboviral disease.
The symptoms most reported by the patients of our study were fever, myalgia, and headache, presented in 90%, 70%, and 60%, respectively, of the DENV-positive patients. These symptoms have also been reported in high frequency by patients recently infected by CHIKV and ZIKV in RS 15 ; therefore, distinction among these arboviral diseases relies on other symptoms. In this regard, arthralgia, which is observed in more than 80% of patients infected by CHIKV, was reported by only 40% of the patients infected by DENV, similar to what is reported for ZIKV 15 ; on the other hand, we found that more than 20% of DENVinfected patients displayed leucopenia, which is observed in only 10%
of CHIKV cases and is not reported in ZIKV cases. 15 An important factor that must be considered is that the surveillance system adopted in Brazil investigates biological samples ity of a person to be infected by an arbovirus twice; thus, the chance of cross-reactivity is minimum. In the present study, we followed the Brazilian guidelines for dengue diagnosis, which we have also used in a previous study about DENV surveillance before the introduction of CHIKV and ZIKV in RS. 2 Considering that these arboviruses were recently introduced in the state and that most of the population had not been exposed to them before, there is little chance that a falsepositive DENV case occurred in this study due to cross-reactivity. In addition, areas where we observed high incidence of DENV such as the missionary region ( Figure 3 ) had low prevalence of CHIKV and ZIKV. 15 Regardless of that, it is important to keep in mind that the DENV IgM assays might still lead to wrong conclusions that DENV caused an epidemic that was actually caused by another flavivirus; therefore, our approach combining laboratory results, clinical symptoms, and epidemiological characteristics of the case is extremely important to accurately diagnose the disease and treat the patient and also for surveillance of arboviruses.
With respect to DENV-negative patients, many displayed exanthema and hence were investigated for other diseases such as Chikungunya and Zika (data not shown); some were negative for these arboviral diseases, but positive for parvovirus. Of note, inves- income inequality, and human development index for the incidence and recurrence of dengue fever in RS. 22 The latter shows that, in RS, DENV outbreaks occur in clusters, with a "contagious process" between neighboring municipalities; therefore, dengue should be seen as a regional rather than a municipal concern. Our analyses also show the occurrence of DENV cases in clusters of municipalities, reinforcing the necessity of a broader approach in the fight against dengue, including more rigorous sampling, collection of detailed epidemiological and clinical data and, further, the development of more sensitive and specific assays.
